Drug intelligence / Profile preview

ferric pyrophosphate citrate + heparin

Development stage
Unknown
Lead developer
Rockwell Medical
Modality
Small Molecules
Administration
Intravenous
01

Overview

This is a **combination of ferric pyrophosphate citrate and unfractionated heparin** administered intravenously during hemodialysis. Ferric pyrophosphate citrate is an iron replacement agent designed to maintain iron balance by providing soluble iron, which is rapidly chelated by transferrin and incorporated into hemoglobin for erythropoiesis, bypassing the macrophage-mediated iron sequestration seen with traditional IV iron[1][3]. Unfractionated heparin is an anticoagulant that enhances the activity of antithrombin III, inactivates thrombin and factor Xa, and is widely used in dialysis to maintain circuit patency. Clinical studies confirm **no significant pharmacokinetic or pharmacodynamic drug-drug interactions when ferric pyrophosphate citrate is co-administered with unfractionated heparin as a single admixture, and each retains its efficacy and safety profile for iron delivery and anticoagulation**[1][2][3].

Brand names
Triferic AVNU
Other names
ferric pyrophosphate citrate and unfractionated heparin admixture
02

Targets

F2 (Thrombin)F10 (Factor Xa)ATIII (Antithrombin III)

Beyond the preview

Go deeper on ferric pyrophosphate citrate + heparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ferric pyrophosphate citrate + heparin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call